Drug intelligence / Profile preview

VaxiFlu

Development stage: Approved
Lead developer: Zydus Lifesciences
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**VaxiFlu** is a Zydus Lifesciences seasonal **trivalent inactivated influenza vaccine** developed for prevention of influenza. The identifiable VaxiFlu product launched in India for the 2025–2026 Northern Hemisphere season contains influenza A/H1N1pdm09, influenza A/H3N2, and influenza B/Victoria-lineage vaccine strains. As an inactivated split-virion vaccine, it presents influenza viral antigens, including hemagglutinin, to induce strain-specific humoral immune responses and protective neutralizing antibodies. It is administered by intramuscular injection and is intended for annual seasonal vaccination because circulating influenza strains can change between seasons.

Brand names: VaxiFlu

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on VaxiFlu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaxiFlu.

Explore the full profile